United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 21,512 shares of the company’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $112.55, for a total transaction of $2,421,175.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
United Therapeutics Co. (UTHR) traded down $2.01 on Wednesday, reaching $111.88. 373,708 shares of the company were exchanged, compared to its average volume of 459,948. The firm has a market cap of $5,018.83, a P/E ratio of 11.98 and a beta of 1.32. United Therapeutics Co. has a 12-month low of $107.82 and a 12-month high of $152.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.01 and a current ratio of 3.26.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.59 by $0.30. The firm had revenue of $464.70 million during the quarter, compared to the consensus estimate of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.12 EPS. analysts expect that United Therapeutics Co. will post 12.46 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Focused Wealth Management Inc acquired a new stake in United Therapeutics during the 4th quarter worth approximately $139,000. Quantbot Technologies LP increased its position in United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 822 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $178,000. JOYN Advisors Inc. acquired a new stake in United Therapeutics during the 4th quarter worth approximately $201,000. Finally, HL Financial Services LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $217,000.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.